Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread
and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained …

Since the discovery of penicillin, β-lactam antibiotics have commonly been used to treat
bacterial infections. Unfortunately, at the same time, pathogens can develop resistance to β …

ABSTRACT Ceftazidime/avibactam (CAZ-AVI), approved in 2015, is an important first-line
option for KPC-producing Enterobacterales (KPC-E). Although still uncommon, resistance to …

The β-lactams have a central place in the antibacterial armamentarium, but the increasing
resistance to these drugs, especially among Gram-negative bacteria, is becoming one of the …

As a class, the β-lactams are the most commonly prescribed and clinically dependable
antimicrobials in the United States, representing more than 65% of injected antibiotic …

ABSTRACT From January 2019 to April 2020, 32 KPC-producing, ceftazidime-avibactam
(CZA)-resistant Klebsiella pneumoniae strains were isolated in a university hospital in …

Background Healthcare-associated infections involving Gram-negative bacteria (GNB) with
difficult-to-treat resistance (DTR) phenotype are associated with impaired patient-centered …

Klebsiella pneumoniae carbapenemase (KPC)-producing Pseudomonas aeruginosa (KPC-
PA) has been reported sporadically. However, epidemiological and antimicrobial …

Abstract Ceftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐
lactamase inhibitor (avibactam) that has been approved by the US Food and Drug …

Abstract Objectives Carbapenemase-producing Enterobacterales represent a major cause
of difficult-to-treat infections world-wide. Novel β-lactam/β-lactamase inhibitor combinations …